Summary of Significant Accounting Policies - Narrative (Details)		1 Months Ended			12 Months Ended
	May 09, 2022	Sep. 30, 2020 USD ($)	Jan. 31, 2020 USD ($)	Oct. 31, 2014 USD ($)	Dec. 31, 2022 USD ($) agreement	Dec. 31, 2021 USD ($)	Dec. 31, 2016 USD ($)	Jun. 30, 2021 USD ($)
Accounting Policies [Abstract]
Number of distribution and license agreements | agreement					5
Customers average payment term					30 days
Distributors average payment term					45 days
Summary of significant accounting policies
Net revenue					$ 72,810,000	$ 61,931,000
Impairment losses					0	0
Bad-debt expense					0	0
Contract assets					0	0
Revenue performance obligation					2,900,000	8,200,000
Stock split, conversion ratio	0.1
Impairments of long-lived assets					$ 0	0
Finite-lived intangible asset useful life					17 years
Recognized revenue					$ 2,500,000	1,900,000
Contract liabilities					4,331,000	8,157,000
Research and product development expense					3,119,000	6,835,000
Baxter Healthcare Organization
Summary of significant accounting policies
Distribution agreement term				10 years
Upfront payment				$ 20,000,000
Contract liabilities					1,500,000	5,200,000
Wanbang Biopharmaceutical
Summary of significant accounting policies
Upfront payment							$ 4,000,000
Recognized revenue					200,000	200,000
Contract liabilities					2,300,000	2,500,000
Sun Pharma Agreements
Summary of significant accounting policies
Upfront payment			$ 100,000
Recognized revenue					10,000	10,000
Contract liabilities					100,000	100,000
Jeil Pharma Agreements
Summary of significant accounting policies
Upfront payment		$ 400,000
Recognized revenue					18,158	10,000
Contract liabilities					400,000	200,000
Drogsan Pharma Agreements
Summary of significant accounting policies
Recognized revenue					15,000	7,500
Contract liabilities					$ 100,000	100,000		$ 150,000
Minimum
Summary of significant accounting policies
Property and equipment useful life					3 years
Market and performance-based stock unit awards service period					1 year
Maximum
Summary of significant accounting policies
Property and equipment useful life					10 years
Market and performance-based stock unit awards service period					2 years
License
Summary of significant accounting policies
Net revenue					$ 2,700,000	2,200,000
Product
Summary of significant accounting policies
Net revenue					70,100,000	59,700,000
Upfront Fee | Baxter Healthcare Organization
Summary of significant accounting policies
Recognized revenue					2,500,000	1,900,000
Total Concentrate Products
Summary of significant accounting policies
Net revenue					71,651,000	60,855,000
Reserve for returns					$ 0	$ 0